Why the study?
Do amlodipine and ramipril have differential effects on TAFI levels in patients with primary hypertension?
Do amlodipine and ramipril have differential effects on TAFI levels in patients with primary hypertension?
TAFI levels are elevated in primary hypertension and are reduced by amlodipine but not ramipril, indicating potential differences in fibrinolytic effects among antihypertensive agents.
Answers are grounded in this paper and cite their sources.
May indicate class-specific fibrinolytic effects in hypertension; hypothesis-generating and requires randomized confirmation before clinical consideration.
Hypertension is associated with fibrinolysis abnormality. Thrombin-activatable fibrinolysis inhibitor (TAFI) is a novel molecule-linking coagulation and fibrinolysis. The aim of this study was to investigate the levels of TAFI in primary hypertensive patients and to compare the effects of amlodipine and ramipril on TAFI levels. The study was performed with 58 hypertensive subjects and 27 healthy volunteers. Biochemical and hematological parameters and TAFI levels were measured at baseline and after 1-month follow-up. TAFI concentrations increased in hypertensive patients compared with the controls (P = .030). Additionally, TAFI levels decreased with blood pressure control at 1-month follow-up (P = .026). There was no significant difference between TAFI levels in the amlodipine and ramipril groups at baseline. However, after 1-month follow-up, TAFI levels were decreased in the amlodipine group (P = .037) but not in the ramipril group. Our study is the first in the literature to determine increased TAFI levels in primary hypertension patients. In addition, we determined a decrease in TAFI levels in the amlodipine group after 1 month, but none in the ramipril group.
No takes yet. Share an insight, caveat, or question.
Özkan et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: